4//SEC Filing
ROSENBERG MORRIS 4
Accession 0001104659-19-015613
CIK 0000722830other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 4:35 PM ET
Size
8.0 KB
Accession
0001104659-19-015613
Insider Transaction Report
Form 4
IMMUNOMEDICS INCIMMU
ROSENBERG MORRIS
See Remarks
Transactions
- Award
Stock Option (right to buy)
2019-03-14+42,760→ 42,760 totalExercise: $17.94Exp: 2026-03-14→ Common Stock, par value $0.01 per share (42,760 underlying) - Award
Stock Option (right to buy)
2019-03-14+25,000→ 25,000 totalExercise: $17.94Exp: 2026-03-14→ Common Stock, par value $0.01 per share (25,000 underlying)
Footnotes (2)
- [F1]The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.
- [F2]The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.
Documents
Issuer
IMMUNOMEDICS INC
CIK 0000722830
Entity typeother
Related Parties
1- filerCIK 0001202786
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 4:35 PM ET
- Size
- 8.0 KB